Statistics

Total Visits

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)23

Select a period of time:

Number of views in the range

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)13

Views

Views
May 20241
June 20242
July 20243
August 20242
September 20242
October 20242
November 20241
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States13
 

Top cities views

Views
Chicago2
Fort Worth1